Revvity to Acquire Human Cell Design to Expand Metabolic and GLP-1 Drug Discovery Tools
September 11, 2026
Revvity entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human pancreatic beta cell models and preclinical research solutions for diabetes, obesity, and other metabolic diseases. The acquisition is expected to strengthen Revvity’s life sciences tools for drug discovery, screening, and preclinical research, including next-generation GLP-1 and other metabolic therapies.
- Buyers
- Revvity, Inc.
- Targets
- Human Cell Design
- Industry
- Biotechnology
- Location
- France
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.